In a report released today, Silvan Tuerkcan from Oppenheimer reiterated a Buy rating on Constellation Pharmaceuticals Inc (CNST), with a price target of $14. The company’s shares opened today at $9.78.
“CNST reported FY18 results with $114.6M in year-end cash, which should fund operations into 2Q20. In January, CNST announced new data from the ongoing Ph2 MANIFEST trial in ruxolitinib-resistant second-line MF patients with the BET inhibitor CPI-0610. Additional interim data from ~18-20 evaluable patients will be presented in 2Q19. CPI-1205 Ph1b data from ProSTAR in mCRPC will be presented at AACR (4/1). Enrollment in Ph2 portion is on track; data will be available in 2H19. We reiterate our Outperform rating ahead of several PoC readouts in 2019 and increase our PT to $14 from $11, based on “heavily pretreated” patient data. Our estimates change, due to 4Q model updates. We believe the risk/reward profile is positive ahead of AACR based on previous data and anticipate a potential upside of $3 (Exhibits 1-6).”
Tuerkcan has an average return of 115.0% when recommending Constellation Pharmaceuticals Inc.
According to TipRanks.com, Tuerkcan is ranked #2094 out of 5259 analysts.
Constellation Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $15.33.
The company has a one-year high of $12.45 and a one-year low of $4.01. Currently, Constellation Pharmaceuticals Inc has an average volume of 59.21K.
Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CNST in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Constellation Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery, develeopment, and provision of biopharmaceutical products. It researches and develops small molecule therapeutics for the treatment of cancer, inflammatory and immunologic disorders. Its products include CPI-1205, CPI-0209, and CPI-0610.